ADCT announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum for the development and commercialization of Zynlonta for all hematologic and solid tumor indications outside of the US, greater China, Singapore and Japan. ADC Therapeutics is eligible to receive up to $435 million, including $55 million upfront, $50 million on first EC approval and up to approximately $330 million in additional regulatory and sales milestones. Separately, ADCT announced that first patient has been dosed in China with Zynlonta in combination with rituximab in the LOTIS-5 confirmatory Phase 3 global trial in second-line or later, transplant ineligible patients with DLBCL. First patient was also dosed in Phase 2 trial evaluating Zynlonta in combination with rituximab in unfit and frail patients with previously untreated DLBCL.
Immunogen reported net loss for 2Q 2022 was $62 million, or $0.24 per share, compared to a net loss of $31 million, or $0.15 per share, for 2Q 2021.
The short interest of Mersana decreased in July by 20 % to 4,774,847 on July 15, compared to 6,005,879 on June 15.
Seagen announced positive topline results from the Phase 1b/2 EV-103 trial (KEYNOTE-869) Cohort K evaluating Padcev in combination with Keytruda as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy. In patients treated with Padcev and Keytruda, results demonstrated a 64.5% confirmed ORR. Seagen separately reported net loss for the 2Q 2022 was $135 million, or $0.73 per share, and net loss for the year-to-date in 2022 was $271 million, or $1.48 per share.
Alkermes provided its 2Q 2022 financial results reporting net loss of $30 million for the quarter, or $0.18 per share. This compares to net income of $2 million, or $0.01 per share, for the same period in the prior year.
ImmunityBio announced that FDA accepted for review a BLA from ImmunityBio for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
Nektar announced the promotion of Jillian B. Thomsen to SVP and CFO. Ms. Thomsen has served as SVP, Finance and Chief Accounting Officer of Nektar since 2008, and is a key member of our Executive Committee. Gil Labrucherie, the company's current COO and CFO, will be departing the company to pursue another opportunity at a private biotech.
Xencor will release second quarter 2022 financial results after the market closes on August 3.
Allogene announced the appointment of Stephen L. Mayo PhD to the company’s Board of Directors. Dr. Mayo is the Bren Professor of Biology and Chemistry and Merkin Institute Professor at the California Institute of Technology.
Autolus attended the William Blair’s Biotech Focus Conference 2022. Autolus’ CEO Christian Itin participated in a panel discussion on ‘Operationalizing Cell Therapies.’
The short interest of Bellicum decreased in July by 32 % to 109,427 on July 15, compared to 161,687 on June 15.
Mustang announced that the first patient successfully received LV-RAG1 ex vivo lentiviral gene therapy to treat recombinase-activating gene-1 severe combined immunodeficiency, in an ongoing Phase 1/2 multicenter clinical trial taking place in Europe. LV-RAG1 is first-in-class ex vivo lentiviral gene therapy for treatment of the disease.
Arcus will participate in a virtual fireside chat at the 13th Annual Wedbush PacGrow Healthcare Conference.
Immutep announced the grant of a new patent entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office. This new Japanese patent follows the grant of the equivalent European patent announced in October 2020.
Clovis had Type A meeting with the FDA to discuss its plans for a supplemental marketing application for Rubraca as a first-line maintenance treatment in ovarian cancer. FDA recommended that the company wait for more mature overall survival data to submit the application.